Navigation Links
URMC heart research expands to Asia with launch of new device trial
Date:8/9/2013

Cardiologists at the University of Rochester Medical Center are launching a new study in an effort to improve the treatment of a very common form of heart disease in the Asian population.

Called MADIT-Asia, the study is the first to test cardiac resynchronization therapy a device that improves the mechanical pumping action of the heart in Asian patients with non-coronary heart disease. Though the majority of heart disease in the United States is caused by cholesterol-clogged arteries that restrict blood flow from the coronary arteries to the heart, the opposite is true in Asia, where there's a much higher proportion of heart disease that's caused by virus or, in many cases, unknown factors.

"This study is important because there has been almost no research related to the treatment of non-ischemic or non-coronary heart disease in this population; most trials have taken place in the United States and Europe," noted principal investigator Arthur J. Moss, M.D., cardiology professor at the University of Rochester Medical Center and a leading expert on cardiac device therapy.

Moss says the study is also the first to test an innovative approach using two leads or wires instead of the usual three to send electrical impulses from the cardiac resynchronization therapy device to the heart to help it beat in a more balanced way. The leads, which are positioned in specific spots in the heart at the time of device implantation, can get infected, fracture, or even pierce a vein if not positioned properly by a skilled clinician.

"Preliminary evidence suggests that a two-lead system is just as effective, if not more effective, than a three-lead system," said Moss. "Fewer leads would be better and would most likely translate into fewer complications for patients."

The trial, sponsored by Boston Scientific, will enroll 180 patients from China, Hong Kong (part of China, but medically it operates differently), Japan, South Korea, Taiwan, Singapore, Thailand, Malaysia and India. Half of the patients will receive cardiac resynchronization therapy using two leads plus standard medical management and the other half will be managed medically. The team, which is ready to enroll the first patients in the trial, will use echocardiogram readings to determine improvement in heart function in each group.

This is the latest trial in the series of MADIT (Multicenter Automatic Defibrillator Implantation Trial) studies, which Moss has led since their inception in the early 1990's. His major findings include: Preventive therapy with an implantable cardioverter defibrillator or ICD significantly reduces the risk of death in heart attack survivors; cardiac resynchronization therapy plus defibrillator (CRT-D therapy) prevents the progression of heart failure in patients living with mild forms of the disease; and a simple change in the way physicians program CRT-D devices dramatically reduces inappropriate therapies potentially painful shocks delivered for rhythms that aren't life threatening and significantly increases survival in people with heart disease.

Moss holds no stock in any device company, has never been a member of any corporate speakers bureau and since December 1, 2008, has chosen not to accept honoraria from Boston Scientific for any professional activity.


'/>"/>

Contact: Emily Boynton
emily_boynton@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Heartburn No More System Review Exposes New Efficient Heartburn Treatment
2. Study: Heart pump with behind-the-ear power connector
3. Santa Rosa Boot Camp Celebrates Successful 1,000lb Meltdown Challenge by Donating All Proceeds to the American Heart Association
4. UC Davis "Lab on a Chip" Measures Heart Disease Risk
5. MedHelp to Host Online Chat on How Cancer Treatment Can Affect Heart Health
6. AED.com Encourages Kidd Kraddick Fans to Examine Their Heart Health
7. Beaumont Health System Launches Research Trial of Bioresorbable Heart Scaffold
8. Researchers identify genetic mutation linked to congenital heart disease
9. Beaumont Health System launches research trial of bioresorbable heart scaffold
10. A Checklist for Heart Attack Prevention, from the July 2013 Harvard Men's Health Watch
11. Increased Risk of Heart Disease Associated With Long-Term Obesity Article Published by Health News Wires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 ... survey data released today by the American Society for Dermatologic Surgery ... the percentage of consumers considering a cosmetic medical procedure has doubled since 2013. ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on the ... Louisiana became the sixth state to pass legislation which ensures that children can ... signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington who ...
(Date:6/27/2017)... York, NY (PRWEB) , ... June 27, 2017 ... ... and marketing experts to contribute to an upcoming case studies guidebook. This guidebook ... her organization. , This book will include articles, case studies and how-to’s that ...
(Date:6/27/2017)... ... June 27, 2017 , ... Today, June 27th is PTSD Awareness Day. ... than 20% will receive adequate care due to lack of effective treatments, fear of ... at all. And left untreated, veterans are at an increased risk for self-destructive behavior, ...
(Date:6/26/2017)... ... 2017 , ... Antoine Dental Center is now offering various types of dental implants ... as a support for prosthetic teeth, such as crowns, bridges, or dentures. An implant is ... sturdy, lasting new root for the tooth. , Several types of dental implants are ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... Datascope Corp. is voluntarily performing a worldwide field correction of certain Intra-Aortic Balloon ... ... CS100i ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX 0998-00-3023-XX;  ... This field correction also applies to any System 98 ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... U.S. Food and Drug Administration (FDA) has notified the Company ... its Zhejiang, China manufacturing facility has ... successful clearance of the Warning Letter related to our ... measure of the progress we have made in our ongoing ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, 2017 ... with diabetes. In a further effort to help spread ... by this condition, the International Diabetes Federation (IDF) and ... have come together for the second phase of the ... programme (BRIDGES 2), reaffirming their commitment to helping people ...
Breaking Medicine Technology: